Kupando Raises €10 Million in Series A Funding
Kupando, a Berlin-based biopharmaceutical company focused on combating cancer and infectious diseases, has successfully secured €10 million in a Series A funding round. This round, announced on March 18, 2026, was led by Remiges Ventures and LifeCare Partners, with participation from Brandenburg Kapital, High-Tech Gründerfonds, Ventura Biomed Investors, and Carma Fund.
Company Vision and Leadership
Kupando is at the forefront of developing innovative treatments for cancer and infectious diseases. The company is led by CEO and Founder Johanna Holldack, who has been instrumental in steering its strategic direction. Under her leadership, Kupando aims to leverage this new funding to enhance its research capabilities and accelerate the development of its therapeutic pipeline.
Strategic Use of Funds
While specific details on the allocation of the new funds were not disclosed, it is anticipated that the capital will be used to advance Kupando's research and development efforts. This could potentially include expanding their scientific team, enhancing laboratory facilities, and accelerating clinical trials for their promising therapies.
Investor Confidence
The substantial investment from both lead and participating investors reflects a strong confidence in Kupando's potential to make significant breakthroughs in the biopharmaceutical field. The involvement of notable firms such as Remiges Ventures and LifeCare Partners underscores the strategic importance of Kupando's research focus.
Location and Impact
Operating out of Schönefeld, Brandenburg, Germany, Kupando is well-positioned within a region known for its robust biopharmaceutical and research ecosystem. This geographical advantage provides the company with access to a wealth of scientific talent and resources, further supporting its ambitious goals.
With this latest funding round, Kupando is set to strengthen its position in the biopharmaceutical industry, driving forward its mission to develop effective treatments for some of the world's most challenging health issues.